Abstracts Archive - Page 2411 of 2607 - ACR Meeting Abstracts

Abstract Number: 318 • 2013 ACR/ARHP Annual Meeting
Effect Of Brodalumab (AMG 827) On Pain and Physical Functioning In Patients With Psoriatic Arthritis
MC Genovese¹, Philip J. Mease², Hema Viswanathan³, Dina Chau³, JingYuan Feng³, Ngozi Erondu³ and Ajay Nirula³, ¹Stanford University, Palo Alto, CA, ²Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ³Amgen Inc, Thousand Oaks, CA
Background/Purpose: Psoriatic arthritis (PsA) has a significant impact on health related quality of life (HRQoL). This analysis evaluated the efficacy of brodalumab, a human anti-IL-17…
Abstract Number: 319 • 2013 ACR/ARHP Annual Meeting
Secukinumab Shows Substantial Improvement In Both Psoriasis Symptoms and Physical Functioning In Moderate-To-Severe Plaque Psoriasis Patients With Psoriatic Arthritis: A Subanalysis Of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study
Alice B. Gottlieb¹, Bardur Sigurgeirsson², Andrew Blauvelt³, Shephard Mpfofu⁴, Ruvie Martin⁵ and Charis Papavassilis⁴, ¹Tufts Medical Center, Boston, MA, ²University of Iceland, Kópavogur, Iceland, ³Oregon Health and Sciences University, Portland, OR, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharma AG, East Hanover, NJ
Background/Purpose: Since interleukin (IL)-17A has a potential role in the pathogenesis and chronic inflammation of psoriatic disease, with similar pathways impacting skin and joints, strategies…
Abstract Number: 288 • 2013 ACR/ARHP Annual Meeting
MRI Findings In Juvenile Spondyloarthopathy and Effects Of Treatment On Subsequent MRI
Clara Lin¹ and Diana Milojevic², ¹Pediatric Rheumatology, University of California-San Francisco, San Francisco, CA, ²Dept of Pediatric Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: : The aim of our study was to describe pelvic MRI findings of juvenile spondyloarthopathy describe the treatment effects on subsequent MRIs in juvenile…
Abstract Number: 280 • 2013 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy Of Etanercept In Paediatric Subjects With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Or Psoriatic Arthritis
Tamas Constantin¹, Ivan Foeldvari², Jelena Vojinovic³, Gerd Horneff⁴, Ruben Burgos-Vargas⁵, Irina Nikishina⁶, Jonathan Akikusa⁷, Tadej Avcin⁸, Jeffrey Chaitow⁵, Elena Koskova⁹, Bernard Lauwerys¹⁰, Jack Bukowski¹¹, Chuanbo Zang¹², Joseph Wajdula¹², Deborah Woodworth¹², Bonnie Vlahos¹³, Alberto Martini¹⁴ and Nicolino Ruperto⁵, ¹Semmelweis University, Budapest, Hungary, ²Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, ³Dept Pediatric Rheumatology, Clinical Center, School of Medicine University of Nis, Nis, Serbia, ⁴Department of Pediatrics, Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁵PRINTO, Genoa, Italy, ⁶Pediatric Department, Scientific Research Institute of Rheumatology RAMS, Moskow, Moskow, Russia, ⁷Rheumatology, Royal Childrens Hospital, Parkville, Australia, ⁸The Ljubljana University Medical Centre, Pediatric Clinic, Ljubljana, Slovenia, ⁹National Institute of Rheumatic Diseases, Piestany, Slovakia, ¹⁰Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ¹¹Department of Specialty Care, Pfizer Inc, Collegeville, PA, ¹²Pfizer Inc., Collegeville, PA, ¹³Department of Specialty Care, Pfizer Inc., Collegeville, PA, ¹⁴Pediatria II, Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Etanercept (ETN) is approved for the treatment of pediatric patients with the polyarticular subtype of juvenile idiopathic arthritis (JIA). In addition, based on the…
Abstract Number: 281 • 2013 ACR/ARHP Annual Meeting
GO-Kids Imaging Substudy: MRI Treatment Response To 30 Mg/m² 4-Weekly Subcutaneous injections Of Golimumab In Children With Polyarticular JIA – Preliminary Results Of The Open Label Portion
Nikolay Tzaribachev¹, Catrin Tzaribachev¹ and Bernd Koos², ¹Pediatric Rheumatology, PRI - Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, ²Clinic of Orthodontics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany
GO-KIDS Imaging Substudy: MRI treatment response to 30 mg/m2 4-weekly subcutaneous injections of Golimumab in children with polyarticular JIA– preliminary results of the open label…
Abstract Number: 282 • 2013 ACR/ARHP Annual Meeting
Rates Of Flare-Free Survival In Juvenile Idiopathic Arthritis When Tapering Individual Components Of Tumor Necrosis Factor Inhibitor and Methotrexate Combination Therapy
Caroline Y Chang¹, Rika Meyer² and Andreas Reiff¹, ¹Division of Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, ²Children's Hospital Los Angeles, Los Angeles, CA
Background/Purpose: Combination therapy of tumor necrosis factor inhibitors (TNFi) and methotrexate (MTX) is a well-established treatment that has dramatically changed outcomes in Juvenile Idiopathic Arthritis…
Abstract Number: 283 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Biologic Treatments In Juvenile Idiopathic Arthritis With a Polyarticular Course: An Indirect Comparison
Laura Sawyer¹, Alex Diamantopoulos², Hermine Brunner³, Fabrizio De Benedetti⁴, Nicolino Ruperto⁵, Fred Dejonckheere⁶ and Caroline Keane⁷, ¹Symmetron Limited, London, United Kingdom, ²Symmetron Limited, Herts, United Kingdom, ³PRCSG, Cincinnati, OH, ⁴Division of Rheumatology, Department of Pediatric Medicine, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ⁵PRINTO, Genoa, Italy, ⁶F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁷Roche, Welwyn Garden City, United Kingdom
Background/Purpose: To date there are no head-to-head trials comparing the efficacy of biologic treatments for polyarticular-course JIA (pcJIA). The purpose of this study was to…
Abstract Number: 284 • 2013 ACR/ARHP Annual Meeting
What Is the Relative Priority of the ACR Pediatric Core Set Measures for Youth With Juvenile Idiopathic Arthritis and Their Parents?
Jaime Guzman¹, Oralia Gomez-Ramirez², Susanne M. Benseler³, Roberta A. Berard⁴, Rollin Brant⁵, Ciaran M. Duffy⁶, Roman Jurencak⁷, Kiem Oen⁸, Ross E. Petty⁹, Natalie J. Shiff¹⁰ and Lori B. Tucker¹¹, ¹Pediatric Rheum/Rm K4-122, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ²Anthropology, University of British Columbia, Vancouver, BC, Canada, ³Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Children's Hospital of Western Ontario, London, ON, Canada, ⁵Statistics, University of British Columbia, Vancouver, BC, Canada, ⁶Rheumatology, Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ⁷University of Ottawa, Ottawa, ON, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹Pediatric Rheumatology, BC Children's Hosptial, Vancouver, BC, Canada, ¹⁰Pediatric Rheumatology, University of Saskatchewan, Saskatoon, SK, Canada, ¹¹Rheumatology, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: The ACR has endorsed a core set of six measures to assess the course of JIA and the impact of treatment: active joint count,…
Abstract Number: 285 • 2013 ACR/ARHP Annual Meeting
Juvenile Idiopathic Arthritis Patients Demonstrate Alterations In HDL Functionality Without Accelerated Subclinical Atherosclerosis
Preethi Mani¹, Kiyoko Uno², Katherine Wolski³, Steven J. Spalding⁴, Stephen J. Nicholls⁵ and M. Elaine Husni⁶, ¹Cleveland Clinic Lerner College of Medicine, Cleveland, OH, ²Cardiovascular medicine, Cleveland Clinic Foundation, Cleveland, OH, ³Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH, ⁴Pediatric Institute, Department of Pediatric Rheumatology, The Cleveland Clinic, Cleveland, OH, ⁵Clinical Research Heart & Vascular Institute, Cleveland Clinic Foundation, Cleveland, OH, ⁶Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Previous literature supports an increase in cardiovascular (CV) morbidity and mortality in adults with inflammatory joint disease, however it is not known whether children with…
Abstract Number: 286 • 2013 ACR/ARHP Annual Meeting
Cardiovascular Risk In Adults With Juvenile Idiopathic Arthritis
Elizabeth Coulson¹, Wan-Fai Ng², Philip N. Platt³ and H. E. Foster⁴, ¹Rheumatology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ²Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle upon Tyne, United Kingdom, ³Rheumatology, Freeman Hospital, Newcastle upon Tyne, United Kingdom, ⁴Paediatric Rheumatology, Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University and Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom
Background/Purpose: Increased cardiovascular mortality and morbidity have been observed in adults with Rheumatoid Arthritis. The long-term risk of cardiovascular disease for individuals with Juvenile Idiopathic…
Abstract Number: 287 • 2013 ACR/ARHP Annual Meeting
Long-Term Evaluation Of Cardiac Function In Juvenile Idiopathic Arthritis Under Anti-Tumor Necrosis Factor Therapy
Alessandro C. Lianza¹, Nadia E. Aikawa², Julio C. B. Moraes³, Gabriela N. Leal⁴, Samira S. Morhy⁵, Eloisa Bonfa⁶ and Clovis A. Silva⁷, ¹Radiology, University of São Paulo, Sao Paulo, Brazil, ²Rheumatology, University of São Paulo, Sao Paulo, Brazil, ³Reumatologia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Radiology Division, University of São Paulo, Sao Paulo, Brazil, ⁵Radiology Unit, University of São Paulo, Sao Paulo, Brazil, ⁶Rheumatology Division, University of São Paulo, Sao Paulo, Brazil, ⁷Children's Institute, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil
Background/Purpose: Subclinical cardiac involvement was previously described in juvenile idiopathic arthritis (JIA) patients, however there is no data regarding echocardiography and cardiac biomarkers evaluations in…
Abstract Number: 289 • 2013 ACR/ARHP Annual Meeting
Development and Validation Of The Cutoff Values For Disease Activity States Of The Three-Item Version Of The Juvenile Arthritis Disease Activity Score
Alessandro Consolaro¹, Sara Verazza¹, Maria C. Gallo¹, Giulia Bracciolini¹, Giorgia Negro¹, Alessia Frisina¹, Nicolino Ruperto², Alberto Martini^1,3 and Angelo Ravelli^1,3, ¹Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ²PRINTO, Genoa, Italy, ³Department of Pediatrics, University of Genova, Genova, Italy
Background/Purpose: A new approach to the measurement of disease activity in juvenile idiopathic arthritis (JIA) is based on the Juvenile Arthritis Disease Activity Score (JADAS).…
Abstract Number: 290 • 2013 ACR/ARHP Annual Meeting
Children With JIA Show Distinct Patterns Of Improvement In Their Health-Related Quality Of Life During The First Year On Treatment: Growth Mixture Modeling Of a Prospective Cohort Of Newly Diagnosed Patients
Bin Huang¹, Chen Chen², Stacey Niehaus³, Hermine Brunner⁴, Rina Mina⁵ and Michael Seid⁶, ¹Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH, ²Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH, ⁵Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Pulmonary, Cincinnati Children's Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH
Background/Purpose: Health-related quality of life (HRQOL) is a key outcome in clinical care and research for children with JIA. Despite excellent clinical control and the…
Abstract Number: 292 • 2013 ACR/ARHP Annual Meeting
Body Surface Area-Based Dosing Approach Produced Comparable Golimumab Exposure Across Different Age Ranges After Subcutaneous Administration Of Golimumab In Pediatric Patients With Juvenile Idiopathic Arthritis
Jocelyn H. Leu¹, Alan M. Mendelsohn², Joyce Ford¹, Hugh M. Davis¹ and Zhenhua Xu¹, ¹Janssen Research & Development, LLC., Spring House, PA, ²Immunology, Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: To evaluate the pharmacokinetics (PK) of body surface area (BSA)-adjusted dosing of SC golimumab 30 mg/m2 every 4 weeks (q4w) + methotrexate (MTX)…
Abstract Number: 293 • 2013 ACR/ARHP Annual Meeting
The Efficacy Of Etanercept In Patients With Juvenile Idiopathic Arthritis With Inadequate Response To Infliximab As a First TNF Inhibitor
Ekaterina Alekseeva^1,2, Tatyana Bzarova³, Anna Fetisova³, Tatyana Sleptsova³, Saniya Valieva³, Kseniya Isayeva³, Rina Denisova³, Elena Mitenko³, Evgeniya Chistyakova³ and Nikolay Taybulatov⁴, ¹PRINTO, Genoa, Italy, ²I.M.Sechenov First Moscow State Medical University, Moscow, Russia, ³Rheumatology, Scientific Center of Children's Health of RAMS, Moscow, Russia, ⁴Orthopedic, Scientific Center of Children's Health of RAMS, Moscow, Russia
Background/Purpose: Lack of efficacy of Methotrexate, primary and secondary resistance to biologics and their intolerance lead to juvenile idiopathic arthritis (JIA) of progression. Therefore, the problem of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].